Drug Interactions between Fyarro and One A Day Men's Complete
This report displays the potential drug interactions for the following 2 drugs:
- Fyarro (sirolimus protein-bound)
- One A Day Men's Complete (multivitamin with minerals)
Interactions between your drugs
No interactions were found between Fyarro and One A Day Men's Complete. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Fyarro
A total of 408 drugs are known to interact with Fyarro.
- Fyarro is in the drug class mTOR inhibitors.
- Fyarro is used to treat Malignant Perivascular Epithelioid Cell Tumor.
One A Day Men's Complete
A total of 103 drugs are known to interact with One A Day Men's Complete.
- One a day men's complete is in the drug class vitamin and mineral combinations.
- One a day men's complete is used to treat Vitamin/Mineral Supplementation and Deficiency.
Drug and food interactions
sirolimus protein-bound food
Applies to: Fyarro (sirolimus protein-bound)
GENERALLY AVOID: Coadministration of protein-bound sirolimus intravenous suspension with grapefruit juice may increase the systemic exposure to sirolimus. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of sirolimus by certain compounds present in grapefruit. However, grapefruit juice primarily inhibits CYP450 3A4-mediated first-pass metabolism in the gut wall and may have limited effects on medications that are not administered orally. No formal studies evaluating the drug interaction potential of protein-bound sirolimus have been conducted. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.
MANAGEMENT: The manufacturer recommends avoiding grapefruit and grapefruit juice during treatment with protein-bound sirolimus.
References (1)
- (2022) "Product Information. Fyarro (sirolimus protein-bound)." Aadi Bioscience, Inc.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.